Skip to main content

Table 4 Point estimates of the incremental cost-effectiveness ratios (ICER) for PoC testing per patient maintained in the target range* compared with laboratory testing

From: The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial

Test Treatment Group Costs per patient ($) Effects per patient * ICER ($)
INR Intervention (PoCT) 3,298 0.5701  
  Control (Laboratory) 3,150 0.6147  
  Difference 148 -0.0446 Dominated
HbA1c Intervention (PoCT) 3,676 0.6548  
  Control (Laboratory) 3672 0.5618  
  Difference 4 0.0930 $40
ACR Intervention (PoCT) 1,727 0.7739  
  Control (Laboratory) 1,954 0.7418  
  Difference -228 0.0321 Dominant
Lipids Intervention (PoCT) 2,732 0.1592  
  Control (Laboratory) 2,202 0.1066  
  Difference 530 0.0526 $10,082
  1. *Effect is the proportion of patients in target range as determined at the end of the Trial (18 months mean observation time)